Save time and get answers to complex questions with AI chat
Is it okay to take anti histamine when on statins?Patent expiry trametinib?Patent expiration eu dabrafenib?Bivalirudin manufacturer?When will latisse patent expire?
What are the current phases of clinical development for Pf-06650833? Pf-06650833, also known as crisaborole, is an ointment being developed by Pfenex Inc. for the treatment of mild to moderate atopic dermatitis [1]. The ointment contains a proprietary formulation of the active pharmaceutical ingredient (API) crisaborole, which is a small molecule inhibitor of Janus kinase (JAK) enzymes. Has Pf-06650833 completed phase 3 clinical trials? Yes, Pf-06650833 has completed a phase 3 clinical trial, known as Study EFC10668, in patients with mild to moderate atopic dermatitis [1]. The trial aimed to evaluate the efficacy and safety of the ointment in reducing the severity of atopic dermatitis symptoms. Has Pf-06650833 received FDA approval? Yes, Pf-06650833, branded as Eucrisa, received FDA approval in March 2016 [2] for the treatment of mild to moderate atopic dermatitis in patients aged 2 years and older. The approval was based on the results of a phase 3 clinical trial and a post-marketing safety study. What is the patent status of Pf-06650833? According to DrugPatentWatch, the US Patent for Pf-06650833 is expected to expire in August 2033 [3]. Where can I find more information on Pf-06650833 clinical development? More information on Pf-06650833 clinical development can be found on the Pfenex Inc. website, as well as on clinicaltrials.gov, which lists clinical trials registered on the site [4]. Sources: [1] ClinicalTrials.gov. (2019). EFC10668: A Randomized, Controlled Study of Crisaborole in Mild to Moderate Atopic Dermatitis. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02310280 [2] U.S. Food and Drug Administration. (2016). FDA Approves Eucrisa (crisaborole) Ointment, 2%, for Mild to Moderate Atopic Dermatitis. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-eucrisa-crisaborole-ointment-2-mild-moderate-atopic-dermatitis [3] DrugPatentWatch. (2023). Crisaborole Patent Expiration. Retrieved from https://www.drugpatentwatch.com/patents/US-9830173-B2/crisaborole/ [4] ClinicalTrials.gov. (2023). Pf-06650833 Clinical Trials. Retrieved from https://clinicaltrials.gov/ct2/results?cond=&term=Pf-06650833&cntry=&cntrygrp=&state=&city=&country=&dist=&spons=Pfenex+Inc&gpdc=1&searchtype=quick&agev=E&recr=Open&acrd=E&recrd=E&prev=
Other Questions About Clinical :